Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Abivax (ABVX) over the last 4 years, with Dec 2024 value amounting to -$2.99.

  • Abivax's EPS (Weighted Average and Diluted) fell 28.85% to -$0.86 in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.40, marking a year-over-year decrease of 70.72%. This contributed to the annual value of -$2.99 for FY2024, which is 18.92% up from last year.
  • According to the latest figures from FY2024, Abivax's EPS (Weighted Average and Diluted) is -$2.99, which was up 18.92% from -$3.69 recorded in FY2023.
  • Abivax's EPS (Weighted Average and Diluted)'s 5-year high stood at -$2.99 during FY2024, with a 5-year trough of -$3.69 in FY2023.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$3.35 (2022), whereas its average is -$3.34.
  • In the last 5 years, Abivax's EPS (Weighted Average and Diluted) declined by 10.11% in 2023 and then rose by 18.92% in 2024.
  • Yearly analysis of 4 years shows Abivax's EPS (Weighted Average and Diluted) stood at -$3.25 in 2021, then fell by 2.99% to -$3.35 in 2022, then dropped by 10.11% to -$3.69 in 2023, then increased by 18.92% to -$2.99 in 2024.